세계의 중증하지허혈(CLI) 치료 시장 : 기회, 성장 촉진요인, 산업 동향 분석 및 예측(2024-2032년)

The Global Critical Limb Ischemia (CLI) Treatment Market, valued at USD 4.2 billion in 2023, is set to grow at a CAGR of 6.7% from 2024 to 2032. CLI, a severe manifestation of peripheral artery disease, restricts blood flow to the limbs, leading to pain, ulcers, and potential limb amputation. Due to advancements in medical technology, revascularization procedures have seen improved outcomes, playing a pivotal role in restoring blood flow and averting limb loss.

Moreover, advancements in vascular imaging technologies have sharpened the precision in diagnosing CLI and planning revascularization. Tools, such as duplex ultrasound, computed tomography angiography (CTA), and MRI systems provide intricate vascular images, crucial for assessing blockage severity and location. These enhanced diagnostics not only streamline treatment but also elevate patient outcomes.

The overall critical limb ischemia treatment industry is categorized based on treatment type, end-use, and region.

The market, segmented by treatment type, includes procedures, medications, and other treatments. Dominating the market, the procedures segment was valued at USD 2.9 billion in 2023. Encompassing revascularization techniques like angioplasty, stent placement, atherectomy, and surgical bypass, this segment is vital for restoring blood flow in CLI patients, preventing limb loss, and enhancing outcomes.

End-use segmentation of the CLI treatment industry includes hospitals, ambulatory surgical centers, and others. The hospitals segment is projected to grow at a 7% CAGR through 2032. As primary venues for CLI diagnosis and treatment, hospitals cater to the complexities of this severe peripheral artery disease. They provide a full spectrum of care, from diagnosis and imaging to surgical and post-operative care. Advanced imaging tools, including duplex ultrasound and CT angiography, empower hospitals to gauge arterial blockages accurately and devise suitable treatment plans.

North America CLI treatment market was valued at USD 1.7 billion in 2023. North America's leadership in the global CLI treatment arena is underscored by its advanced healthcare system, ensuring widespread access to cutting-edge diagnostic and therapeutic tools. The region's heightened prevalence of CLI-related risk factors, such as diabetes and hypertension, fuels a strong demand for diverse treatment options, spanning pharmacological therapies to surgical interventions.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of peripheral artery disease (PAD)
    • 3.2.1.2 Technological advancements in revascularization procedures
    • 3.2.1.3 Growing awareness and early diagnosis
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High cost of advanced treatments
• 3.3 Growth potential analysis
• 3.4 Technology landscape
• 3.5 Future market trends
• 3.6 Regulatory landscape
• 3.7 Product pipeline analysis
• 3.8 Reimbursement scenario
• 3.9 Porter's analysis
• 3.10 GAP analysis
• 3.11 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Treatment Type, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Procedures
  • 5.2.1 Endovascular procedures
    • 5.2.1.1 Angioplasty
    • 5.2.1.2 Stenting
    • 5.2.1.3 Atherectomy
  • 5.2.2 Surgical procedures
    • 5.2.2.1 Bypass surgery
    • 5.2.2.2 Endarterectomy
• 5.3 Medications
  • 5.3.1 Antiplatelet drugs
  • 5.3.2 Anticoagulants
  • 5.3.3 Cholesterol-lowering drugs
  • 5.3.4 Pain relievers
  • 5.3.5 Other medications
• 5.4 Other treatment types

Chapter 6 Market Estimates and Forecast, By End-use, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Hospitals
• 6.3 Ambulatory surgical centers
• 6.4 Other end-users

Chapter 7 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 North America
  • 7.2.1 U.S.
  • 7.2.2 Canada
• 7.3 Europe
  • 7.3.1 Germany
  • 7.3.2 UK
  • 7.3.3 France
  • 7.3.4 Spain
  • 7.3.5 Italy
  • 7.3.6 Netherlands
  • 7.3.7 Rest of Europe
• 7.4 Asia Pacific
  • 7.4.1 China
  • 7.4.2 Japan
  • 7.4.3 India
  • 7.4.4 Australia
  • 7.4.5 South Korea
  • 7.4.6 Rest of Asia Pacific
• 7.5 Latin America
  • 7.5.1 Brazil
  • 7.5.2 Mexico
  • 7.5.3 Argentina
  • 7.5.4 Rest of Latin America
• 7.6 Middle East and Africa
  • 7.6.1 South Africa
  • 7.6.2 Saudi Arabia
  • 7.6.3 UAE
  • 7.6.4 Rest of Middle East and Africa

Chapter 8 Company Profiles

• 8.1 Abbott Laboratories
• 8.2 Bayer
• 8.3 Boston Scientific
• 8.4 Cesca Therapeutics
• 8.5 Cook Medical
• 8.6 Eli Lilly and Company
• 8.7 Medtronic plc
• 8.8 Micro Medical Solutions
• 8.9 Pfizer
• 8.10 Sanofi
• 8.11 Terumo Corporation
• 8.12 Teva Pharmaceuticals